| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T90 |
0-11 |
Sentence |
denotes |
Baricitinib |
| T91 |
12-302 |
Sentence |
denotes |
The SARSCoV and the 2019nCoV both enters host cells through ACE2 receptormediated entry, especially through AT2 cells present in lungs.[36] Downstream signaling of this receptor mediates the endocytosis process, and AP2-associated protein kinase 1 (AAK1) plays a major role in this process. |
| T92 |
303-345 |
Sentence |
denotes |
Thus, AAK1 represents an important target. |
| T93 |
346-455 |
Sentence |
denotes |
Richardson et al., 2020 evaluated 378 ligands, of which 47 were already approved for use in other conditions. |
| T94 |
456-515 |
Sentence |
denotes |
Among these ligands, six inhibited AAK1 with high affinity. |
| T95 |
516-630 |
Sentence |
denotes |
Considering the side effect profile, they found janus kinase inhibitor baricitinib to be the most important agent. |
| T96 |
631-745 |
Sentence |
denotes |
In addition to AAK1, baricitinib also binds to another endocytosis regulator protein (cyclin G-associated kinase). |
| T97 |
746-893 |
Sentence |
denotes |
Thus, the authors suggest that baricitinib can be evaluated in the in vitro conditions as well as in the clinical trial settings for 2019-nCoV.[37] |
